J Int Assoc Provid AIDS Care by Ahonkhai, Aimalohi A. et al.
Impact of Unplanned Care Interruption on CD4 Response Early 
After ART Initiation in a Nigerian Cohort
Aimalohi A. Ahonkhai, MD, MPH1,2,3, Juliet Adeola, BSc, MBA4, Bolanle Banigbe, MD, 
MPH4, Ifeyinwa Onwuatuelo, BDS, MPH4, Abdulkabir B. Adegoke, MD, MPH2, Ingrid V. 
Bassett, MD, MPH1,2,3,5, Elena Losina, PhD2,3,5,6,7, Kenneth A. Freedberg, MD, 
MSc1,2,3,5,8,9,10, Prosper Okonkwo, MD, FMPCH3, and Susan Regan, PhD2,5,8
1Division of infectious Disease, Massachusetts General Hospital, Boston, MA, USA
2Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
3Harvard Medical School, Boston, MA, USA
4AIDS Prevention Initiative in Nigeria (APIN), Abuja, Nigeria
5Harvard University Center for AIDS Research (CFAR), Boston, MA, USA
6Department of Orthopedic Surgery, Brigham and Women’s Hospital, Boston, MA, USA
7Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
8Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA
9Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA
10Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, 
Boston, MA, USA
Abstract
The authors conducted a retrospective cohort study of unplanned care interruption (UCI) among 
adults initiating antiretroviral therapy (ART) from 2009 to 2011 in a Nigerian clinic. The authors 
used repeated measures regression to model the impact of UCI on CD4 count upon return to care 
and rate of CD4 change on ART. Among 2496 patients, 83% had 0, 15% had 1, and 2% had ≥2 
UCIs. Mean baseline CD4 for those with 0, 1, or ≥2 UCIs was 228/cells/mm3, 355/cells/mm3, and 
392/cells/mm3 (P < .0001), respectively. The UCI was associated with a 62 CD4 cells/mm3 
decrease (95% confidence interval [CI]: −78 to −45) at next measurement. In months 1 to 6 on 
ART, patients with 0 UCI gained 10 cells/μL/mo (95% CI: 7–4). Those with 1 and ≥2 UCIs lost 2 
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and 5 cells/μL/mo (95% CI: −18 to 13 and −26 to 16). Patients with UCI did not recover from 
early CD4 losses associated with UCI. Preventing UCI is critical to maximize benefits of ART.
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Introduction
Nigeria, the most populous country in Africa, has an estimated 3.5 million people living 
with HIV, the second largest number in the world.1,2 Patient retention in care remains a 
major challenge to successful antiretroviral therapy (ART) administration globally as well as 
in Nigeria.3 With 82% of Nigerians living on less than US$2 per day, those with HIV face 
substantial competing demands for basic subsistence and health-care needs.4
Retention in HIV care requires commitment to health-related visits, including clinical 
evaluations and laboratory testing as well as medication adherence. Studies from sub-
Saharan Africa demonstrate decreasing average retention rates for people living with HIV 
after starting ART, from 80% in the first year to 70% in the third year.3 Outcomes among 
patients not retained in care are often difficult to obtain. Tracking studies suggest that, at one 
extreme, some have transferred but remained engaged in care and others have died.5–7 
Between these extremes, some patients become lost to care, whereas others interrupt but 
later return to care.8–11 Whether short- or long-term, care interruptions represent an obstacle 
to effective care.12–14 Multiple studies in the mid-2000s established that planned treatment 
interruptions increase both morbidity and mortality.15,16
Despite the clear evidence against planned care interruption, unplanned care interruption 
(UCI) is common in both resource-limited and resource-rich environments, occurring in 
14% to 60% of all patients.14,17–19 Like loss to follow-up, the highest UCI rates are in the 
first year after ART initiation, when the most robust CD4 count response is anticipated.19–21 
In Nigeria and other resource-limited settings (RLS), high baseline CD4 count may predict 
subsequent UCI.19 We sought to determine the immunologic consequence of UCI in the first 
year after ART initiation in a Nigerian cohort.
Methods
Setting
This study was conducted at the Ahmadu Bello University Teaching Hospital’s (ABUTH) 
HIV clinic in Kaduna, Nigeria, a state in northern Nigeria with a local HIV prevalence of 
5.1%. The ABUTH HIV clinic is located in a semiurban community and began providing 
HIV care in 2006 with President’s Emergency Plan for AIDS Relief support. ABUTH offers 
comprehensive HIV testing and treatment to nearly 4000 patients. During the study period, 
the clinic was managed by AIDS Prevention Initiative in Nigeria (APIN), one of the largest 
HIV care and treatment programs in Nigeria.22 Upon clinic enrollment, patients completed 
clinical evaluation, tuberculosis screening, adherence counseling, and CD4 count and viral 
load testing. The World Health Organization (WHO) and Nigerian National guidelines 
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recommended ART initiation for all patients with CD4 <350 cells/μL in 2009. After 
enrollment, patients were scheduled to be seen at 2, 4, 8, and 12 weeks for adherence 
counseling and clinical examination. Subsequently, they were seen for ART pickup every 4 
weeks, clinical examination and adherence counseling every 12 weeks, and laboratory 
testing (including CD4 count and HIV viral load) every 24 weeks.23
Care Status Definitions
We conducted a retrospective cohort study of patients ≥15 years of age who initiated ART at 
the ABUTH clinic between January 1, 2009, and December 31, 2011. Data were censored at 
1 year of follow-up, and clinical, laboratory, or pharmacy visits were assessed to determine 
care status. The UCI was defined as a period in which the time between any 2 consecutive 
visits was >90 days, followed by return to clinic (before the censor date). Patients were 
defined as having 0, 1, or ≥2 UCIs in the first year on ART. Patients known to have 
transferred care or died during the follow-up period were categorized based on their visit 
patterns prior to transfer or death.
Data Collection and Analysis
All data were collected in structured data entry forms that were entered into APIN’s central 
electronic clinical database. Patients with an available baseline CD4 count and at least 1 
follow-up value within the first 12 months of initiating ART were included in the analysis. 
We summarized the proportion of patients with 0, 1, or ≥2 UCIs in the first year on ART. We 
used 1-way χ2 tests (for categorical variables) and Kruskal-Wallis tests (for ordinal 
variables) to assess whether the baseline characteristics differed by UCI status. We used a 
locally weighted smoothed scatterplot (LOWESS) curve function to visually assess the 
relationship between time on ART and observed CD4 count for those with 0, 1, or ≥2 UCIs 
in our aggregate data. The LOWESS curve illustrated the expected sharp, early (phase 1), 
and blunted later (phase 2) responses to ART, which occurred in this cohort between months 
1 to 6 and months 7 to 12 on ART.21
To measure the effect of UCI status on CD4 response after ART initiation, we used 2 
repeated measures linear regression models. The first allowed us to determine the short-term 
impact of any UCI on subsequent CD4 count upon return to care, and the second allowed us 
to estimate the longer-term impact by estimating the rate of CD4 change in the first year on 
ART for patients with 0, 1, or ≥2 UCIs. In the first model, we estimated the effect of having 
any UCI on the next measured CD4 count upon return to care. In this model, each patient’s 
total observation time during the first 12 months after ART initiation was divided into 1 or 
more intervals based on the CD4 counts obtained during the period. Each interval was a 
separate observation in the model, which had the change in CD4 count during the interval as 
its dependent variable, and included the patient as a random effect. The primary covariate of 
interest was UCI status, which was assessed as a binary variable indicating whether 0 or any 
UCI occurred since the previous CD4 count. In the second model, we used aggregate CD4 
data to estimate the average rate of CD4 change for patients with 0, 1, or ≥2 UCIs in the first 
year on ART. A spline term was introduced at 6 months after ART initiation to contrast early 
(1–6 months) versus later (7–12 months) effects of UCIs on CD4 count. We also estimated 
the marginal mean CD4 count after 1 year on ART for patients with 0, 1, or ≥2 UCIs, 
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holding all other covariates at their mean values. Both multivariate models included potential 
confounders including age, sex, baseline CD4 count, time since the previous CD4 count, and 
tuberculosis diagnosis at ART initiation.
Statistical analysis was conducted with Stata Statistical Software (Release 13; StataCorp 
2013, College Station, Texas).
Institutional Review Board Approval
Institutional review board approval was obtained from Partners HealthCare (Protocol # 
2013P000219), the Harvard T.H. Chan School of Public Health in Boston, Massachusetts, 
and the Nigerian Institute for Medical Research in Lagos, Nigeria.
Results
Frequency of UCI
The cohort was composed of 2496 patients who initiated ART at the ABUTH clinic during 
the study period. Among all patients, 83% (n = 2058) had no UCI, 15% (n = 376) had 1 
UCI, and 2% (n = 59) had ≥2 UCIs within the first year on ART. Baseline CD4 count at 
ART initiation was not available for 467 patients. Follow-up CD4 counts were not available 
for an additional 380 patients. The remaining 1649 patients who had both a baseline and at 
least 1 follow-up CD4 count in the first year on ART available in the electronic database 
were retained for analysis (the analysis cohort, Figure 1).
Baseline Demographics
The majority of patients in the analysis cohort were female (70%; n = 1163), and the mean 
age was 33 years (standard deviation [SD]: 9.2). Overall, 61% (n = 1004) of patients were 
married and 63% (n = 1027) were employed. Forty-four percent of patients in the cohort (n 
= 734) had primary or secondary education and 34% (n = 559) had tertiary-level education 
(Table 1). The mean baseline CD4 count was 251/μL (SD: 193/μL). Those with ≥2 UCIs had 
a higher mean baseline CD4 of 392/μL (SD: 241/μL) than those with 1 UCI (355/μL; SD: 
228/μL) or no UCI (228/μL; SD: 176/μL; P < .0001). Sixty-three percent (n = 61) of those 
with ≥2 UCIs presented to care with baseline CD4 ≥350/μL compared to 49% of those with 
1 UCI (n = 83), and 18% of those with no UCI (n = 254; P = .0001).
Twenty-four percent of patients in the cohort enrolled and initiated ART with CD4 >350 
cells/μL. We conducted a chart review to determine the reasons for ART initiation in this 
group. All were documented to have met national guideline criteria for starting ART. The 
indication for treatment was advanced WHO stage (3 or 4) in 36%, resumption of ART for 
patients who had discontinued in 20%, concomitant tuberculosis (TB) in 5%, and 
coinfection with hepatitis B virus in 3% of patients. The indication for ART initiation was 
not documented in 36% of patients.
The CD4 Count Assessments
The number of CD4 measurements per patient in the first year on ART ranged from 2 to 7. 
Nineteen percent of patients (n = 314) had 2, 80% (n = 1312) had 3 to 5, and 1% (n = 23) 
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had 6 or 7 CD4 measurements. The median time between CD4 measurements was 105 days 
[interquartile range: 88–140].
Impact of UCI on CD4 Count
We plotted CD4 counts over time since ART initiation during the first year on ART using 
LOWESS smoothing with separate curves for those with 0, 1, and ≥2 UCIs during the year 
(Figure 2). Figure 2 illustrates that patients with no UCI had lower baseline CD4 counts but 
the greatest early rate of CD4 increase in the first 6 months on ART. In contrast, those with 
≥2 UCIs had higher baseline CD4 counts, but early CD4 decrease in the same period.
We assessed the effect of an UCI on the next observed CD4 count in multivariate analysis 
adjusted for patient age, gender, TB coinfection, baseline CD4 count (before ART 
initiation), days since ART initiation, previous CD4 count, and the days since the previous 
CD4 assessment. The CD4 counts increased by an estimated 51 cells/μL (95% confidence 
interval [CI]: 47–55) for each 100 cells/μL increase in baseline CD4 count and decreased by 
11 cells/μL (95% CI: −17 to −5) for each decade increase in patient age. Patients with any 
UCI had 62 fewer CD4 cells at the next CD4 assessment compared to those with no UCI 
(95% CI: −78 to −45).
Impact of 0, 1, or ≥2 UCIs in the First Year on ART on Rate of CD4 Change
In multivariate analysis (adjusted for age, sex, baseline CD4 count, and TB coinfection), 
statistically significant increases in CD4 count were seen only for those with 0 UCI—10 
cells/μL/mo (95% CI: 7–14) in the first 6 months on ART and 4 cells/μL/mo (95% CI: 2–6) 
in months 7 to 12. Patients with UCI did not experience statistically significant gains in the 
first year on ART. Estimated monthly rate of CD4 change in months 1 to 6 was −2 cells/
μL/mo (95% CI: −18 to 13) and −5 cells/μL/mo (95% CI: −26 to 16) for patients with 1 and 
≥2 UCIs, respectively. In months 7 to 12, the estimated rate of CD4 change UCI was 2 cells/
μL/mo (95% CI: −6 to 11) and 8 cells/μL/mo (95% CI: −2 to 7) for patients with 1 and ≥2 
UCIs, respectively (Table 2).
Estimated CD4 Gains After 1 Year on ART
Predicted CD4 count after 1 year on ART was higher for patients with ≥2 UCIs (435 cells/
μL, 95% CI: 347–522) than those with 1 UCI (381 cells/μL, 95% CI: 298–464) or no UCI 
(354 cells/μL, 95% CI: 334–374). However, a comparison of observed baseline CD4 count 
to predicted 12-month CD4 count (holding all other variables in the model at their average) 
showed that patients with no UCI had the greatest CD4 gains at 126 cells/μL (from 228 
cells/μL at baseline). Patients with 1 UCI gained an estimated 26 cells/μL (from 355 cells/μL 
at baseline). Patients with ≥2 UCIs gained 43 CD4 cells/μL (from 392 cells/μL at baseline).
Discussion
We found that unplanned HIV care interruption is common in a large Nigerian treatment 
program. Seventeen percent of patients had at least 1 UCI in their first year on ART. 
Although there is variability in the definition and rates of UCI in the literature, our results 
are consistent with studies conducted in resource-limited and resource-rich 
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settings.10,18,19,24–27 We used several methods to quantify the impact of UCI on immune 
response to ART, all of which demonstrated deleterious effects of interruptions from care. 
The immediate consequence of any UCI was a gain of 62 CD4 cells/μL fewer than those 
who remained in care on the next measured CD4 count. Assessing the longer-term 
consequence of UCI over the first year on ART allowed us to determine whether patients 
with UCI were later able to recover from these early CD4 losses; importantly, they were not. 
Although patients without UCI had substantial CD4 gains, 126 cells/μL over the first year on 
ART, those with 1 or ≥2 UCIs had only one-third of these gains or less. The UCI was among 
the strongest predictors of immunologic recovery after ART initiation, along with baseline 
CD4 count and time on ART.
The first months after starting ART are critical for immune recovery. With effective ART, the 
CD4 response is biphasic. It is characterized by an initial CD4 increase of 50 to 120 cells/μL 
in the first 3 months and a sustained, gradual increase of 2 to 7 cells/μL monthly thereafter, 
which may continue for years.20,28,29 Many factors influence the CD4 response to ART, but 
baseline CD4 count and time on ART are among the most robust predictors; this was also 
illustrated in our analysis.28–31 Studies of patients with chronic HIV infection coinfected 
with TB have shown blunted CD4 responses.32 In our cohort, where only 4% of patients 
were diagnosed with TB upon presentation, baseline TB diagnosis was not a significant 
predictor of CD4 response. Studies on the impact of age on CD4 response have been 
mixed.33–35 We found that older patients exhibited poorer immune recovery. Similarly, data 
on the influence of gender are mixed, and in our cohort, gender did not predict CD4 
response.30,35–37 Even after adjusting for all of these factors (baseline CD4 count, time on 
ART, TB, age, and gender), UCI remained a strong, significant, independent predictor of 
early CD4 response to ART.
We estimated the monthly rate of CD4 increase to be 10 cells/μL/mo in months 1 to 6 after 
starting ART for patients with no UCI. During this period in which patients without UCI 
were seeing their greatest gains, CD4 counts remained stagnant for those with UCI. Our 
findings are consistent with reports from 2 large multicenter cohorts in RLS where monthly 
CD4 increase in the first 6 months on ART ranged from lower estimates of 10 to 16 cells/μL 
to upper estimates of 22 to 23 cells/μL.30,38 Both studies adjust for baseline CD4 and 
gender. Of these 2 studies, only 1 aimed to characterize expected immunologic recovery 
after ART initiation and neither accounted for care interruption.30 Our analysis has allowed 
us to quantify the critical impact of interruptions from care on immune reconstitution.
Our data suggest that patients with higher baseline CD4 counts exhibited more UCIs after 
initiating ART. Patients with ≥2 UCIs started ART with an average of 392 CD4 cells/μL, 
nearly double the average baseline CD4 count of patients with no UCI. However, even when 
adjusting for baseline CD4 count, patients with any UCI had lower CD4 gains than those 
without UCI by the end of their first year in care. As a result, patients with any UCI lost the 
immunologic benefit of both ART and earlier presentation to care. Since patients with UCI 
are partially but not fully engaged in care, they still require the financial and clinical 
investment and commitment of care teams. Ensuring that this investment is not lost is crucial 
not only to individual patients but also for the sustainability of programs as global funding 
for HIV care levels off in Nigeria and other RLS.39,40 Moreover, strategies focusing on 
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increased adherence and linkage to care among patients initiating ART with higher CD4 
counts in Nigeria are even more important considering the recent adoption of WHO 
guidelines recommending immediate ART diagnosis.41
The risk of morbidity and mortality is widely appreciated for patients presenting to care with 
advanced immune suppression and CD4 counts <200 cells/μL.42,43 But the risk of AIDS and 
death persist at higher CD4 strata (as high as 500–650 cells/μL).30,44 This knowledge has 
driven higher global ART initiation thresholds, which increased first to 350 cells/μL then 
500 cells/μL and now to immediate ART.41,45 Furthermore, the absolute risk of AIDS and 
death is higher in RLS regardless of CD4 count, likely due to the higher burden of TB and 
invasive bacterial disease.46 These findings underscore the importance of maximizing the 
immune response to ART and adherence to care irrespective of the baseline CD4 counts.
Our study has important limitations. Since it was conducted in an urban environment at 1 
university-affiliated clinic, it may not be fully generalizable to other settings. Nonetheless, 
our estimates of CD4 gains in the first year after starting ART are consistent with those from 
other RLS. In addition, our analysis of the impact of UCI on CD4 response to ART was 
restricted to patients who had available baseline and at least 1 follow-up CD4 result. Missing 
CD4 values could have biased our estimates in either direction, but since more patients 
excluded from the analysis had UCI than those included, our estimates are likely to be 
conservative. Finally, our estimates of CD4 recovery may have been biased by the finding 
that patients with more UCI had higher median CD4 counts at ART initiation and thus had 
less capacity for immunologic recovery as assessed by CD4 gains on ART. Our models did 
adjust for baseline CD4 count to address this potential bias.
Despite these limitations, this analysis also has several strengths. Our robust electronic 
health record allowed us to quantify the frequency of UCI by relying on a range of health-
care visits (clinical, laboratory, and pharmacy) over the first year on ART. With nearly one-
tenth of the global population of people living with HIV in Nigeria, this setting is critical for 
assessing the impact of ineffective retention in care. Our analysis is one of the few providing 
adjusted estimates of the expected immunologic recovery on ART in RLS, where 
background rates of other infections may affect these estimates. As a result, our analysis 
allowed us to illustrate and quantify the immunologic impact of UCI for patients initiated on 
ART. This information can be readily provided at the point of care as a clinical tool to 
reinforce the importance of adherence to care and to demonstrate the impact of care 
interruption on CD4 recovery.
This study underscores that UCI from HIV services is common in RLS and is accompanied 
by a loss in expected therapeutic benefit of ART. Patients with any UCI have both a slower 
rate of CD4 gain and an early loss of CD4 cells that they do not regain over the first year on 
ART. Interventions to prevent UCI, and ensure effective retention in care, are critical to 
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Cohort summary and frequency of unplanned care interruption (UCI) during first year on 
antiretroviral therapy (ART).
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CD4 response by number of unplanned care interruptions in the first year on ART, smoothed 
LOWESS curve. ART, antiretro-viral therapy; LOWESS, locally weighted smoothed 
scatterplot; UCI, unplanned care interruption.
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Table 2
Predicted Rate of CD4 Change in the First Year on ART for Patients with 0, 1, or ≥2 UCIs.a
No UCI 30-Day CD4 Change 95% CI 30-Day CD4 Change 95% CI
Months 0–6 on ART Months 7–12 on ART
0 10 7 to 14 4 2 to 6
1 −2 −18 to 13 2 −6 to 11
≥2 −5 −26 to 16 8 −2 to 17
a
Model adjusted for age, gender, baseline CD4 count, and tuberculosis (TB) coinfection.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval.
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